{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:23:06Z","timestamp":1767918186269,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00277-023-05083-y","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T07:02:50Z","timestamp":1674025370000},"page":"669-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3834-0727","authenticated-orcid":false,"given":"Martin","family":"Stanulla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis M.","family":"Schewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beat","family":"Bornhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Bourquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Eberl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotini","family":"Vogiatzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke K.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Cario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Beier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian P.","family":"Kratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Maecker-Kolhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"5083_CR1","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.3324\/haematol.2019.231720","volume":"105","author":"G Cario","year":"2020","unstructured":"Cario G, Leoni V, Conter V, Attarbaschi A, Zaliova M, Sramkova L, Cazzaniga G, Fazio G, Sutton R, Elitzur S, Izraeli S, Lauten M, Locatelli F, Basso G, Buldini B, Bergmann AK, Lentes J, Steinemann D, G\u00f6hring G et al (2020) Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica 105:1887\u20131894. https:\/\/doi.org\/10.3324\/haematol.2019.231720","journal-title":"Haematologica"},{"key":"5083_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/FTD.0000000000000727","volume":"42","author":"G W\u00fcrthwein","year":"2009","unstructured":"W\u00fcrthwein G, Lanvers-Kaminsky C, Gerss J, M\u00f6ricke A, Zimmermann M, Stary J, Smisek P, Attarbaschi A, Nath C, Zucchetti M, Rizzari C, Schrappe M, Boos J, AIEOP-BFM ALL (2009) Asparaginase Working Party (2020) Therapeutic drug monitoring of asparaginase: intra-individual variability and predictivity in children with acute lymphoblastic leukemia treated with PEG-asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 study. Ther Drug Monit 42:435\u2013444. https:\/\/doi.org\/10.1097\/FTD.0000000000000727","journal-title":"Ther Drug Monit"},{"key":"5083_CR3","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1038\/sj.leu.2403920","volume":"19","author":"U Creutzig","year":"2005","unstructured":"Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, J\u00fcrgens H, Kabisch H, Reiter A, Riehm H, Gadner H, Schellong G (2005) Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 19:2030\u20132042. https:\/\/doi.org\/10.1038\/sj.leu.2403920","journal-title":"Leukemia"},{"key":"5083_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, Shaw PJ, Staciuk R, Ifversen M, Pichler H, Vettenranta K, Svec P, Aleinikova O, Stein J, G\u00fcng\u00f6r T, Toporski J, Truong TH, Diaz-de-Heredia C, Bierings M et al (2021) Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol 39:295\u2013307. https:\/\/doi.org\/10.1200\/JCO.20.02529","journal-title":"J Clin Oncol"},{"key":"5083_CR5","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1182\/bloodadvances.2021006523","volume":"6","author":"K Mizuno","year":"2022","unstructured":"Mizuno K, Dandoy CE, Teusink-Cross A, Davies SM, Vinks AA, Jodele S (2022) Eculizumab precision dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv 6:1454\u20131463. https:\/\/doi.org\/10.1182\/bloodadvances.2021006523","journal-title":"Blood Adv"},{"key":"5083_CR6","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, Richter-Pechanska P, Marovca B, Pail O, Jenni S, Diaz-Flores E, Chang BH, Brown TJ, Collins RH, Uhrig S, Balasubramanian GP, Bandapalli OR, Higi S, Eugster S et al (2017) Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129:e26\u2013e37. https:\/\/doi.org\/10.1182\/blood-2016-09-738070","journal-title":"Blood"},{"key":"5083_CR7","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3324\/haematol.2021.279851","volume":"107","author":"M Cerrano","year":"2022","unstructured":"Cerrano M, Bonifacio M, Olivi M, Curti A, Malagola M, Dargenio M, Scattolin AM, Papayannidis C, Forghieri F, Gurrieri C, Tanasi I, Zappasodi P, La Starza R, Fracchiolla NS, Chiusolo P, Giaccone L, Del Principe MI, Giglio F, Defina M et al (2022) Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. Haematologica 107:996\u2013999. https:\/\/doi.org\/10.3324\/haematol.2021.279851","journal-title":"Haematologica"},{"key":"5083_CR8","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","volume":"128","author":"SL Khaw","year":"2016","unstructured":"Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, Billups CA, Erickson SW, Guo Y, Houghton PJ, Smith MA, Carol H, Roberts AW, Huang DCS, Lock RB (2016) Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood 128:1382\u20131395. https:\/\/doi.org\/10.1182\/blood-2016-03-707414","journal-title":"Blood"},{"key":"5083_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s40364-021-00343-3","volume":"9","author":"S Voruz","year":"2021","unstructured":"Voruz S, Blum S, de Leval L, Schoumans J, Solly F, Spertini O (2021) Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed\/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript. Biomark Res 9:92. https:\/\/doi.org\/10.1186\/s40364-021-00343-3","journal-title":"Biomark Res"},{"key":"5083_CR10","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1182\/bloodadvances.2022007364","volume":"6","author":"F Vogiatzi","year":"2022","unstructured":"Vogiatzi F, Heymann J, M\u00fcller K, Winterberg D, Drakul A, R\u00f6sner T, Lenk L, Heib M, Gehlert CL, Cario G, Schrappe M, Claviez A, Bornhauser B, Bourquin JP, Bomken S, Adam D, Frielitz FS, Maecker-Kolhoff B, Stanulla M et al (2022) Venetoclax enhances the efficacy of therapeutic antibodies in B cell malignancies by augmenting tumor cell phagocytosis. Blood Adv 6:4847\u20134858. https:\/\/doi.org\/10.1182\/bloodadvances.2022007364","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05083-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T06:06:28Z","timestamp":1677650788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05083-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["5083"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05083-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"25 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures reported in our study were in accordance with the ethical standards of the institutional review board of Hannover Medical School and with the 1964 Helsinki declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient and his guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"WE declares advisory board memberships for Bayer and SOBI and received speaker\u2019s honoraria from Bayer, Biotest, Sobi, NovoNordisk, and CSL Behring. WE also received travel support from Bayer, Takeda, NovoNordisk, and CSL Behring. GC and\/or the ALL-BFM study group have received research support from JazzPharma, Servier, Amgen, and Novartis. GC has also received travel support or speaker\u2018s honoraria from Servier, Novartis and JazzPharma. RB received speaker\u2019s honoraria from Medac. BMK declares advisory board membership for Biontech. All other authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}